...has Orphan Drug designation in the U.S. TetraLogic gained the compound through its acquisition of Shape Pharmaceuticals Inc....

...by Healthcare Ventures. TetraLogic declined to disclose financial details, and Shape could not be reached. Shape Pharmaceuticals Inc....

...on epigenetics and cancer gene regulation in the last five years: Acetylon Pharmaceuticals Inc. , Shape Pharmaceuticals Inc....
...Boston, Mass. Harvard Medical School , Boston, Mass. Massachusetts Institute of Technology (MIT), Cambridge, Mass. Shape Pharmaceuticals Inc....

...PI3K) and polo-like kinase 1 (PLK1; STPK13) inhibitor Myelodysplastic syndrome (MDS) Phase III $12.5 M Shape Pharmaceuticals Inc....

...team is developing topically active compounds that limit systemic exposure. Mazitschek is a cofounder of Shape Pharmaceuticals Inc....
...La Jolla, Calif. Massachusetts General Hospital , Boston, Mass. Promedior Inc. , Malvern, Pa. Shape Pharmaceuticals Inc....